Tunis Praises NEJM Editorial Calling On Doctors To Care About Societal Costs
This article was originally published in The Gray Sheet
Executive Summary
Physicians should take more responsibility for demonstrating cost-effectiveness of expensive therapies such as implantable cardioverter defibrillators, according to an editorial in the Dec. 9 issue of the New England Journal of Medicine
You may also be interested in...
Medtronic’s Stanton Stresses The Downsides Of Cost-Effectiveness Analyses
Cost-effectiveness analysis should not be included in Medicare coverage because the methodology is "too immature" and lacks a universal threshold for how much a quality life-year is worth, according to Medtronic Medical Director Marshall Stanton, MD
Medtronic’s Stanton Stresses The Downsides Of Cost-Effectiveness Analyses
Cost-effectiveness analysis should not be included in Medicare coverage because the methodology is "too immature" and lacks a universal threshold for how much a quality life-year is worth, according to Medtronic Medical Director Marshall Stanton, MD
National ICD Registry Proposal Critiqued By Manufacturers, ACC/HRS
CMS' implantable cardioverter defibrillator registry should limit its initial scope to follow-up data at the time of re-hospitalization to keep expenses manageable, according to ICD manufacturers and professional societies